Peapod Lane Capital LLC Takes Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Peapod Lane Capital LLC acquired a new position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 558,418 shares of the company's stock, valued at approximately $888,000. Peapod Lane Capital LLC owned about 0.78% of Zentalis Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in ZNTL. Integral Health Asset Management LLC purchased a new position in Zentalis Pharmaceuticals in the 4th quarter worth approximately $3,182,000. Almitas Capital LLC raised its holdings in Zentalis Pharmaceuticals by 69.3% in the 4th quarter. Almitas Capital LLC now owns 1,626,896 shares of the company's stock worth $4,929,000 after acquiring an additional 665,968 shares during the last quarter. Boxer Capital Management LLC purchased a new position in Zentalis Pharmaceuticals in the 4th quarter worth approximately $1,364,000. JPMorgan Chase & Co. raised its holdings in Zentalis Pharmaceuticals by 75.7% in the 4th quarter. JPMorgan Chase & Co. now owns 859,710 shares of the company's stock worth $2,605,000 after acquiring an additional 370,511 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new position in Zentalis Pharmaceuticals in the 4th quarter worth approximately $703,000.

Insider Activity

In other Zentalis Pharmaceuticals news, Director Scott Dunseth Myers acquired 21,000 shares of the business's stock in a transaction dated Wednesday, April 30th. The stock was purchased at an average price of $1.40 per share, with a total value of $29,400.00. Following the transaction, the director directly owned 281,192 shares in the company, valued at approximately $393,668.80. The trade was a 8.07% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.90% of the stock is currently owned by insiders.

Zentalis Pharmaceuticals Trading Down 2.9%

NASDAQ:ZNTL traded down $0.04 during trading hours on Friday, reaching $1.33. The company had a trading volume of 623,162 shares, compared to its average volume of 1,447,322. Zentalis Pharmaceuticals, Inc. has a 52 week low of $1.01 and a 52 week high of $5.44. The firm has a market cap of $95.69 million, a price-to-earnings ratio of -0.42 and a beta of 1.59. The firm's 50 day moving average price is $1.31 and its 200-day moving average price is $1.76.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, hitting analysts' consensus estimates of ($0.67). On average, analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Wedbush restated a "neutral" rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a research report on Thursday, May 15th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $8.37.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.